Clinical trials: Food-drug Interaction
- Condition Food-drug Interaction
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Inflammatory Bowel Disease
Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study
This is a Phase 1, open-label, 2-cohort, food-effect, DDI, and formulation bridging study.
- Trial name
- NCT03555617
- Testing
- TD-1473, Itraconazole
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Fungal Infection
Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally
This is a Phase l double-blind, placebo-controlled, randomized study to investigate the safety, tolerability, pharmacokinetics, bioavailability and food effect of single doses of APX001 administered intravenously and orally…
- Trial name
- NCT02957929
- Testing
- APX001 single IV dose, APX001 single oral dose 1, APX001 single oral dose 2
- Where
- 2 sites in Netherlands
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Healthy Participants
A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants
This study will be conducted to evaluate the effect of food on the single-dose pharmacokinetics and a drug-drug interaction evaluation of itraconazole and carbamazepine on INCB123667 when administered orally to healthy adult…
- Trial name
- NCT06909162
- Testing
- INCB123667, itraconazole, carbamazepine
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986521 following single and multiple ascending doses of BMS-986521 in healthy adult participants, and to evaluate potential food effects on…
- Trial name
- NCT07283263
- Testing
- BMS-985521
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects
This is a Phase 1, 2-part double-blinded (with respect to NX-5948/placebo), placebo-controlled study. Part 1 is a randomized, 3 period cross-over food-effect (FE) and drug-drug interaction (DDI) study.
- Trial name
- NCT06593457
- Testing
- IP
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Nurix Therapeutics, Inc.
Effect of Food, Pharmacokinetics
Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg
The purpose of the study is to investigate the effects of food, in comparison to fasting conditions, on the extent and rate of absorption of acetylsalicylic acid (ASA) and esomeprazole.
- Trial name
- NCT01163630
- Testing
- esomeprazole/ASA Fixed Dose Combination (FDC)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
Study of BLU-808 in Healthy Adult Participants
This is a 3-part study. Parts 1 and 2 are randomized, double-blind, placebo-controlled investigations of single ascending doses (SAD) (Part 1) and multiple ascending doses (MAD) (Part 2) of orally administered BLU-808 in healthy…
- Trial name
- NCT06948032
- Testing
- BLU-808, Midazolam
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Blueprint Medicines Corporation
HIV Infections
A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults
The aim of the study is to gather information on how the drug behaves in healthy adults, how it is absorbed, and how it interacts when taken with other medicines.
- Trial name
- NCT07066722
- Testing
- VH4524184, Itraconazole, Rifabutin
- Where
- 2 sites in United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy Volunteer
Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers
This trial will consist of three parts: the first two parts will enroll healthy female volunteers into a single ascending dose (SAD) and multiple ascending dose (MAD) treatment groups.
- Trial name
- NCT02846142
- Testing
- PTI-428, ethinyl estradiol and levonorgestrel
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Proteostasis Therapeutics, Inc.
Healthy Volunteers
Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants
The purpose of this study is to evaluate the safety and pharmacokinetics of BMS-986533 in healthy participants receiving single and multiple doses, to assess food and pH effects on the relative bioavailability of BMS-986533, and…
- Trial name
- NCT07629999
- Testing
- BMS-986533, Famotidine, Dabigatran Etexilate
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
First-in-human: Single Ascending Dose, Food Effect, Drug-drug Interaction, Multiple Ascending Dose, Proof of Pharmacology
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending oral doses of ASP6282 in healthy male and female subjects.
- Trial name
- NCT02420782
- Testing
- ASP6282, Itraconazole, Pilocarpine
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy Volunteer, Cystic Fibrosis
Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis
This trial will consist of two parts: Part 1 and Part 2. Part 1 will enroll adult healthy volunteers (HV) into four treatment groups.
- Trial name
- NCT03140527
- Testing
- PTI-801, PTI-808
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- Proteostasis Therapeutics, Inc.
Healthy
Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers
The purpose of this study is to determine whether treatment with a fixed dose combination dapagliflozin/metformin tablet is affected by food.
- Trial name
- NCT01156246
- Testing
- Dapagliflozin/Metformin
- Where
- Sweden
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Drug Interaction Study of MGL-3196 With Pioglitazone
The purpose of this study is to determine whether the single-dose pharmacokinetics (AUC) of pioglitazone are affected by chronic dosing with MGL-3196 100 mg/day in healthy subjects.
- Trial name
- NCT04671056
- Testing
- MGL-3196, Pioglitazone 15mg
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Healthy Subjects
Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949
This is a prospective, single-center, double-blind, randomized, placebo-controlled, ascending single oral dose and food interaction Phase 1 study.
- Trial name
- NCT02099071
- Testing
- ACT-389949 1 mg, ACT-389949 5 mg, ACT-389949 20 mg
- Where
- Netherlands
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Healthy
A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers
The purpose of this study is to assess safety and tolerability of AZD1656 after single ascending oral doses in healthy male subjects
- Trial name
- NCT00726427
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subjects
A Study to Evaluate if ID-085 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects
The objective of this study is to evaluate the tolerability, safety, and pharmacokinetic of single- and multiple-ascending doses of ID-085 in healthy subjects.
- Trial name
- NCT03372629
- Testing
- ID-085
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
A Phase 1 Study of Single and Multiple Ascending Doses of GV-100
This is a first-in-human, multi-part clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), food effect, and drug-drug interaction (DDI) potential of GV-100 following oral administration in healthy…
- Trial name
- NCT07788014
- Testing
- GV-100
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gilva Therapeutics Inc.
Healthy Post Menopausal Women
A Study to Investigate the Effects of Food and Morning Versus Evening on Single and Multiple Doses of ONO-5334 in Healthy Post Menopausal Women
The study will investigate the effects on pharmacodynamics and pharmacokinetics of food and morning versus evening on single and multiple doses of ONO-5334 in healthy post menopausal women.
- Trial name
- NCT01384188
- Testing
- ONO-5334
- Where
- 2 sites in United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects
Study Part I is a single-ascending dose study. Healthy male subjects to be included in the study and randomized in 6 dose groups, Groups A-F (8 subjects per group).
- Trial name
- NCT01954615
- Testing
- 5 mg ACT-281959 prodrug formulation I (Group A), 20 mg ACT-281959 prodrug formulation I (Group B), ACT-281959 prodrug formulation I (Groups C to G doses to be defined)
- Where
- France
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.